{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:53:17Z","timestamp":1788817997960,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.critrevonc.2024.104611","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:03:53Z","timestamp":1736381033000},"page":"104611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"207","author":[{"given":"Hanzala Ahmed","family":"Farooqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Saffi Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wardah Ali","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmah","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shoaib","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104611_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104611_bib2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104611_bib3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4143\/crt.2022.1658","article-title":"Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat."},{"key":"10.1016\/j.critrevonc.2024.104611_bib4","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104611_bib5","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104611_bib6","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab Vedotin: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2024.104611_bib7","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2024.104611_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-024-02356-6","article-title":"Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.critrevonc.2024.104611_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000798","article-title":"Real-world Outcomes of Relapsed\/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy","volume":"6","author":"Argnani","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2024.104611_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hon.2842","article-title":"Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas","volume":"39","author":"Dimou","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104611_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00277-022-05052-x","article-title":"Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey","volume":"102","author":"Dal","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104611_bib12","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/cas.14937","article-title":"A phase 2 study of polatuzumab vedotin +\u2009bendamustine +\u2009rituximab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"112","author":"Terui","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2024.104611_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/ refractory DLBCL: Survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104611_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ejh.13784","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma in the real world","volume":"109","author":"Vodicka","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104611_bib15","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00277-023-05273-8","article-title":"Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)","volume":"102","author":"Rattanathammethee","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104611_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3960\/jslrt.23017","article-title":"Poor clinical outcome of relapsed\/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab","volume":"63","author":"Saburi","year":"2023","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.critrevonc.2024.104611_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104611_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104611_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best. Pr. Res Clin. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104611_bib20","article-title":"FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma","author":"FDA Commissioner","year":"2020","journal-title":"FDA"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2024.104611_bib21","first-page":"2821","article-title":"Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study","volume":"130","author":"Sehn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104611_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104611_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104611_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-142553","article-title":"A Multicenter Real-Life Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Patients with R\/R DLBCL: Preliminary Data on Efficacy and Safety in Chinese Cohort","volume":"136","author":"Wu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104611_bib25","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1182\/blood-2019-123673","article-title":"POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies","volume":"134","author":"McMillan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104611_bib26","doi-asserted-by":"crossref","DOI":"10.2217\/cer-2022-0146","article-title":"Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma","volume":"12","author":"Miller","year":"2023","journal-title":"J. Comp. Eff. Res"},{"key":"10.1016\/j.critrevonc.2024.104611_bib27","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","article-title":"Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"31","author":"Ohmachi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104611_bib28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","article-title":"Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma","volume":"93","author":"Vacirca","year":"2014","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104611_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent Bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104611_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma","volume":"386","author":"Tilly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104611_bib31","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104611_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.25666","article-title":"Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma","volume":"95","author":"Abdulla","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"04","key":"10.1016\/j.critrevonc.2024.104611_bib33","first-page":"356","article-title":"Molecular Classification of Diffuse Large B-Cell Lymphoma","volume":"42","author":"Baa","year":"2021","journal-title":"IJMPO"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104611_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjh.17450","article-title":"Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP \u00b1\u2009ibrutinib","volume":"194","author":"Balasubramanian","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104611_bib35","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104611_bib36","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell\u2013Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104611_bib37","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104611_bib38","doi-asserted-by":"crossref","unstructured":"Caimi, Paolo F. et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology, Volume 22, Issue 6, 790 - 800. \u3008https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(21)00139-X\/abstract\u3009.","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"10.1016\/j.critrevonc.2024.104611_bib39","doi-asserted-by":"crossref","unstructured":"Salles, Gilles et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. The Lancet Oncology, Volume 21, Issue 7, 978 - 988. \u3008https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(20)30225-4\/abstract\u3009.","DOI":"10.1016\/S1470-2045(20)30225-4"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:50Z","timestamp":1740144170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824003548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"alternative-id":["S1040842824003548"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104611","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104611"}}